DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer by Jian Zhu et al.
Zhu et al. Journal of Experimental & Clinical Cancer Research 2012, 31:80
http://www.jeccr.com/content/31/1/80RESEARCH Open AccessDNA Methylation status of Wnt antagonist SFRP5
can predict the response to the EGFR-tyrosine
kinase inhibitor therapy in non-small cell lung
cancer
Jian Zhu1†, Yuyan Wang1†, Jianchun Duan1, Hua Bai1, Zhijie Wang1, Lai Wei2, Jun Zhao1, Minglei Zhuo1,
Shuhang Wang1, Lu Yang1, Tongtong An1, Meina Wu1 and Jie Wang1*Abstract
Background: It is well known that genetic alternation of epidermal growth factor receptor (EGFR) plays critical roles
in tumorgenesis of lung cancer and can predict outcome of non-small-cell lung cancer treatment, especially the
EGFR tyrosine-kinase inhibitors (EGFR-TKIs) therapy. However, it is unclear whether epigenetic changes such as DNA
methylation involve in the response to the EGFR-TKI therapy.
Methods: Tumor samples from 155 patients with stages IIIB to IV NSCLC who received EGFR-TKI therapy were
analyzed for DNA methylation status of Wnt antagonist genes, including SFRP1, SFRP2, SFRP5, DKK3, WIF1, and APC,
using methylation specific PCR (MSP) method. EGFR mutations detections were performed in the same tissues
samples using Denaturing High Performance Liquid Chromatography (DHPLC).
Results: We found that Wnt antagonists tend to methylate simultaneously. Methylation of sFRP1 and sFRP5 are
reversely correlated with EGFR mutation (P = 0.005, P = 0.011). However, no correlations of methylations of other
Wnt antagonist genes with EGFR mutation were found. The patients with methylated SFRP5 have a significant
shorter progression free survival than those with unmethylated SFRP5 in response to EGFR-TKI treatment (P = 0.002),
which is independent of EGFR genotype.
Conclusions: Patients with unmethylated SFRP5 are more likely to benefit from EGFR-TKI therapy.
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Lung cancer is the leading cause of cancer death world-
wide [1]. NSCLC is the most common form of lung can-
cer, accounting for approximately 85% of lung cancer
cases [2,3]. The efficacy of traditional chemotherapy has
reached a plateau [4-6]. Therefore, new approaches are
needed to improve the efficacy of lung cancer therapy. A
number of targeted anticancer agents have been recently
developed and approved for clinical use, among which* Correspondence: wangjie_cc@yahoo.com
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reproduction in any medium, provided the orthe EGFR-TKI has been used as the first-line therapy for
lung cancer patients with EGFR mutations [7-11].
EGFR gene product functions as a receptor tyrosine
kinase that affects cell proliferation and survival by acti-
vating downstream signaling pathways. In 2004, three re-
search groups reported that mutations in the tyrosine
kinase domain of EGFR can predict the responses to
TKIs in NSCLC patients [12-14], which enables the
identification of patient populations that are more likely
to benefit from TKI therapies and serves as the first step
toward personalizing lung cancer therapy. However,
according to the theory of “EGFR addition”, which refers
to the dependency of cancer cells on EGFR mutation to
maintain their malignant phenotypes [15], lung cancer
patients harboring mutations in the tyrosine kinase. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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longer, in response to the EGFR-TKI therapy, than the
actual result. This suggested that EGFR mutation cannot
explain all clinical outcomes of TKI therapy. At least
10 ~ 20% of patients with wild-type EGFR still signifi-
cantly benefit from EGFR-TKI treatment, whereas
around 10% of patients with mutated EGFR are resistant
to the TKI therapy [10,16,17]. In addition, previous stud-
ies reported that both T790M mutation [18] and c-MET
amplification [19] involved in acquired resistance of
EGFR-TKI therapy. Therefore, factors in addition to
EGFR genotype may also contribute to the response to
EGFR-TKI therapy.
The Wingless-type (Wnt) signaling cascade is an im-
portant regulator of embryonic development [20]. Acti-
vation of Wnt signaling pathway leads to elevated
expression of ß-catenin in cytoplasm, which in turn
translocates to the nucleus, interacts with T cell factor/
lymphocyte enhancer factor family, induces, downstream
target genes that regulate cell proliferation and cancer
progression. Aberrant activation of Wnt signaling path-
way has been found in a number of tumors [21], which
can be categorized into the following three common
forms: 1) mutations in APC and/or Axin; 2) aberrant ac-
tivation of Wnt signaling induced by activated EGFR
[22]; 3) methylation of Wnt antagonists. Mutations of
APC and/or Axin are rarely found in lung cancer
patients. In addition, EGFR-TKI treatment blocks activa-
tion of EGFR in patients. Therefore, we hypothesized
that the methylation of Wnt antagonists might signifi-
cantly affect the responses to the EGFR-TKI therapy in
NSCLC patients. Suzuki et al [23] analyzed the syn-
chronous effects and correlations between Wnt antago-
nists and EGFR mutations and found that EGFR
mutation was correlated with a good prognosis in
tumors without methylated wnt antagonist genes.
In current study, we analyzed the methylation status
of the CpG sites within Wnt antagonist genes, including
SFRP1, SFRP2, SFRP5, WIF1, DKK3, APC, and CDH1, in
155 Chinese patients who received EGFR-TKI therapy
and investigated potential clinical implication of the epi-
genetic regulation of Wnt antagonists.
Methods
Patients
155 patients were enrolled in current study. They were
pathologically diagnosed as stage IIIB or IV NSCLC, with
Eastern Cooperative Oncology Group performance
(ECOG) status of 0 to 2; and received EGFR-TKI as either
first- or second-line therapy at the Peking University
Cancer Hospital between June 2006 and December 2009.
The study was reviewed and approved by the Institutional
Review Board at the Beijing Cancer Hospital. Written
informed consent was obtained from all participants.The smoking status of patients was decided during
their first visit. A smoker was defined as the one who
smoked more than 100 cigarettes in his/her life time.
Patients were treated with either TKI therapy or
platinum-based chemotherapy as the first line of treat-
ment until their disease progressed, justified by imaging
evidence or aggravated symptoms. The Response Evalu-
ation Criteria in Solid Tumors (RECIST) [24] including
progressive disease (PD), stable disease (SD), partial re-
mission (PR) and complete remission (CR) was used to
evaluate the drug response after patients received treat-
ment every 6 weeks to 2 months. The objective response
rate (ORR) was defined as the sum of PR and CR, while
the disease control rate (DCR) was defined as the sum
of SD, PR, and CR. Progression-free survival(PFS) was
assessed from the beginning of therapy to disease pro-
gress or death from any cause. Overall survival(OS) was
assessed from the beginning of first-line therapy until
death from any cause.
DNA extraction and methylation-specific PCR
Genomic DNA of tumor tissues from patients biopsied
before TKI treatment were extracted using QIAmp FFPE
DNA kit (Qiagen). The methylation status of the CpG
sites within the gene loci of SFRP1, SFRP2, SFRP5,
WIF1, DKK3, APC, and CDH1 was decided by MSP
assays as described previously [25-27]. Briefly, genomic
DNA was treated with sodium bisulfite, followed by PCR
amplifications using the primer pairs that can specific
detect either the methylated or the unmethylated CpG
sites. Genes were defined as methylated if the PCR pro-
ducts could be detected using the methylated DNA-
specific primer pairs, while they were defined as
unmethylated if the PCR products could only be
detected using the unmethylated DNA-specific primer
pairs. DNA from the human adenocarcinomic alveolar
basal epithelial cell lines, A549 and A549/DDP, was used
as the positive control for methylated DNA, while DNA
from lymphocytes of healthy nonsmoking volunteers
was used as the negative control. The methylation status
results were confirmed by at least one repeat of the

































The denaturing high-performance liquid chromatog-
raphy (DHPLC) was used to detect mutations in the
exon 19 and 21 of EGFR tyrosine kinase domains as
described previously [28].
Statistical analysis
All data were analyzed using SPSS (version 16.0).
Chi-square and Fisher’s exact tests were used to assess the
association between DNA methylation and EGFR geno-
types. Multivariate analysis was performed using Cox pro-
portional hazard regression model. The Kaplan-Meier




SFRP1 SFRP2 SFRP5 DKK3
Gander
Male (74) 30 (40.5) 20 (27.0) 9 (12.2) 9 (12.2)
Female (81) 31 (38.3) 20 (24.7) 14 (17.3) 13 (16.0)
Age
<65 (89) 33 (37.1) 21 (23.6) 10 (11.2) 12 (13.5)
≥65 (66) 28 (42.4) 19 (28.8) 13 (19.7) 10 (15.2)
Smoking
Never (93) 35 (37.6) 24 (25.8) 14 (15.1) 15 (16.1)
Smokers (62) 26 (41.9) 16 (25.8) 9 (14.5) 7 (11.3)
Histology
Adenocarcinoma (118) 46 (38.9) 30 (25.4) 16 (13.6) 16 (13.6)
Non-adenocarcinoma (37) 15 (40.5) 10 (27.0) 7 (18.9) 6 (16.2)
Total 61 (39.4) 40 (25.8) 23 (14.8) 22 (14.2)
*The frequency of this group is significantly higher than their counterparts.progression-free survival curves. P value less than 0.05
was considered statistically significant.
Results
Characteristics of study patients
Table 1 summarized the demographic characteristics of 155
study patients, among which 118 cases were adenocarcin-
oma and 37 cases were non- adenocarcinoma (29 squamous
carcinoma, 5 large cell carcinoma, and 3 adeno- squamous
carcinoma cases). 60 of all patients received EGFR-TKI as
the first-line therapy, while the rest had EGFR-TKI as the
second- or more-line treatment. Among those 95 patients
who had EGFR-TKI as the second- or more-line treatment,
63 patients took platinum-based chemotherapy as the first-
line treatment. The median follow-up time for all patients
was 22.4 months (from 2.4 to 77.2 months).
Epigenotype of Wnt antagonists in NSCLC
Genomic DNA was extracted from tumor tissues of all
patients as described in the Method Section. The methyla-
tion status of Wnt antagonist genes including SFRP1,
SFRP2, SFRP5, WIF1, DKK3, APC, and CDH1, defined as
their epigenotype, was detected by Methylation Specific
PCR Assays (examples were shown in Additional file 1:
Figure S1A). The frequency of methylation events in Wnt
antagonist genes in patients with different demographic
characteristics was listed in Table 1. Interestingly, no sig-
nificant difference in epigenotype of Wnt antagonist genes
was found between male and female, among different age
groups, between smokers and non-smokers, or between
adenocarcinoma and non-adenocarcinoma cases.
Using DHPLC, we also detected EGFR activating muta-
tions in exon 19 or 21 (the examples of wild type, mutatedation (%) EGFR mutation (%)
WIF1 APC CDH1 Any gene
3 (4.1) 13 (17.6) 7 (9.5) 44 (59.5) 36 (48.6)
3 (3.7) 18 (22.2) 8 (9.9) 48 (59.3) 49 (60.5)
3 (3.4) 16 (18.0) 7 (7.9) 48 (53.9) 56 (62.9)*
3 (4.5) 15 (22.7) 8 (12.1) 44 (66.7) 29 (43.9)
2 (2.2) 21 (22.6) 8 (8.6) 58 (62.4) 57 (61.3)*
4 (6.5) 10 (16.1) 7 (11.3) 34 (54.8) 28 (45.2)
4 (3.4) 21 (17.8) 14 (11.9) 72 (61.0) 65 (55.1)
2 (5.4) 7 (18.9) 1 (2.7) 20 (54.1) 20 (54.1)
6 (38.7) 31 (20%) 15 (9.7%) 92 (59.4%) 85 (54.8%)
Table 2 P value among methylated genes and EGFR mutation
sFRP1 sFRP2 sFRP5 DKK3 WIF-1 APC CDH-1 EGFR mutation
sFRP1 NA 0.004 0.005 0.008 0.02 <0.0001 0.266 0.005
sFRP2 0.004 NA <0.0001 <0.0001 0.007 <0.0001 <0.0001 0.854
sFRP5 0.005 <0.0001 NA <0.0001 <0.0001 0.06 <0.0001 0.011
DKK3 0.008 <0.0001 <0.0001 NA 0.0001 0.006 <0.0001 0.489
WIF-1 0.02 0.007 <0.0001 <0.0001 NA 0.03 0.02 0.094
APC <0.0001 <0.0001 0.06 0.006 0.03 NA 0.126 0.546
CDH-1 0.266 <0.0001 <0.0001 <0.0001 0.02 0.126 NA 0.592
EGFR 0.005 0.854 0.011 0.489 0.094 0.546 0.592 NA
mutation
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file 1: Figure S1B, 1C, and 1D). Among the 155 patients,
85 (55.4%) carried mutations in either exon 19 or 21 of the
EGFR genes (Table 1).Similar to the previous studies, we
found that EGFR mutation rates were significantly
increased among the patients younger than 65 years old
(P= 0.02, Fisher’s exact test) and the patients who are non-
smokers (P= 0.04, Fisher’s exact test). EGFR mutation re-
versely correlates with sFPR1 methylation (P= 0.005) and
sFRP5 (P= 0.011). We fail to find methylation of other wnt
antagonist genes correlated with EGFR mutation (Table 2).
We next investigated whether the epigenotype of any
Wnt antagonist genes correlated with the genotype of
EGFR. Hierarchical clustering of the epigenotype of
SFRP1, SFRP2, SFRP5, WIF1, DKK3, APC, and CDH1, as
well as the genotype of EGFR (defined as “1” if mutationWIF1 CDH1 DKK3 SFR
Figure 1 Hierarchical clustering of Wnt antagonist DNA methylation s
therapy. Red represents methylated gene or mutated EGFR, while blue rep
hierarchical clustering showed that the epigenotype of Wnt antagonist gen
EGFR.was detected in the exon 19 or 21, and as “0” if no muta-
tion was detected) was generated using Partek Genomics
Suite 6.5 (Partek Inc., MO). As shown in Figure 1, the
epigenotype of Wnt antagonist genes had similar pat-
terns, which were different from the genotype of EGFR.
Therefore, our results suggested that the DNA methyla-
tion of Wnt antagonist might be independently regulated
from the genotype of EGFR.
Epigenotype of Wnt antagonist genes and clinical
responses to TKI therapy
The RECIST was used to evaluate the clinical response
of all patients to the TKI therapy. By the end of our
study, 59 (38.1%), 53 (33.2%), 43 (27.7%) patients were
defined with PD, SD, or PR, respectively. We then calcu-
lated the ORR and DCR and analyzed the differenceP5 SFRP2 APC SFRP1 EGFR
mutation
tatus and EGFR genotype in 155 patients received EGFR-TKI
resents unmethylated gene or wild-type EGFR, The figure of
es had similar patterns, which were different from the genotype of
Table 3 Multivariate statistic of gender, age, histology, smoking status, treat line, EGFR mutation and SFRP5
methylation for objective response rate (ORR) and disease control rate (DCR)
Variable Objective response rate (ORR) Disease control rate (DCR)
Univariate Multivariate Univariate Multivariate
P value P value Hazard ratio
(95% CI)
P value P value Hazard ratio
(95% CI)
Gender (male / female) 0.188 0.881 0.926 (0.337-2.542) 0.001 0.115 2.117 (0.834-5.734)
Age (≤65 / >65) 0.351 0.078 2.295 (0.912-5.772) 0.291 0.791 1.110 (0.515-2.393)
Histology (adenocarcinoma / nonadenocarcinoma) 0.002 0.006 6.680 (1.712-26.057) 0.049 0.244 1.663 (0.707-3.915)
Line Treatment (first line / not-first line) 0.016 0.078 2.184 (0.917-5.200) 0.940 0.491 0.756 (0.341-1.678)
Smoking Status (smoker / nonsmoker) 0.016 0.262 0.526 (0.171-1.617) 0.001 0.188 0.524 (0.200-1.371)
EGFR Mutation (wide type / mutation) <0.0001 <0.0001 7.695 (2.895-20.454) <0.0001 0.002 3.255 (1.540-6.881)
SFRP5 Methylation (methylated / unmethylated) 0.222 0.650 0.734 (0.193-2.788) 0.04 0.106 0.434 (0.158-1.193)
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acteristics, as well as with different genotypes of EGFR
and epigenotypes of Wnt antagonist genes. As shown in
Table 3, when only single factor was considered, the
histology of the cancer (adenocarcinoma/nonadenocarci-
noma), line treatment of TKI therapy (first line/not- first
line), as well as smoking status (smoker/nonsmoker) sig-
nificantly affected the ORR to the TKI therapy. Similarly,
the gender (male/female), the histology of the cancer
(adenocarcinoma/nonadenocarcinoma) as well as smo-
king status (smoker/nonsmoker) were found to signifi-
cantly affect the DCR of the TKI therapy. However, when
all demographic characteristics were considered, only the
histology of the cancer (P= 0.006, 95% CI, 1.712-26.057,
multivariate logistic regression) was associated with ORR.
Previous studies have indicated that EGFR mutation
significantly affected the ORR and DCR of the TKI ther-
apy. Consistently, we found that the genotype of EGFR
significantly affected the ORR (P < 0.0001, 95% CI,
2.895-20.454, multivariate logistic regression adjusted by
gender, age, histology, line treatment, and smoking sta-
tus) and the DCR (P = 0.002, 95% CI, 1.540-6.881, multi-
variate logistic regression adjusted by gender, age,
histology, line treatment, and smoking status) (Table 3).Figure 2 Kaplan-Meier curves are shown comparing the progression
WIF1 (B), different genotype of EGFR (C), or SFRP5 in adenocarcinomaOur results confirmed the higher response rate to the
TKI therapy among patients with EGFR mutations as
compared to the patients with wild-type EGFR.
Next, we investigated whether epigenotype of Wnt
antagonists correlated with the clinical responses rate of
the TKI therapy. Our univariate analysis identified the
epigenotype of SFRP5 as the only potential factor signifi-
cantly affecting DCR but not ORR (P = 0.04). However,
the positive association of SFRP5 with DCR was not
confirmed in multivariate analysis. When we sub-
grouped patients based on their demographic character-
istics, we found that SFRP1 methylation significantly
reduced DCR in patients older than 65 (P = 0.038) and
sFRP5 methylation significantly reduced DCR in patients
suffered adenocarcinoma (P = 0.042).
Epigenotype of Wnt antagonists and progression-free
survival (PFS)
We next analyzed whether the epigenotypes of Wnt
antagonists could predict the PFS in response to the TKI
therapy. The median PFS time in all patients was
5.1 months (ranging from 0.4 month to 38 months).
Interestingly, as shown in Figure 2A, patients with
methylated SFRP5 gene had significantly shorter medianfree survival of patients with different epigenotypes of SFRP5 (A),
with EGFR mutation group (D).
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http://www.jeccr.com/content/31/1/80PFS time (1.2 months, 95% CI, 0.5-1.9) as compared to
those with unmethylated SFRP5 gene (6.1 months, 95%
CI, 4.4-7.8) (P = 0.002, Logrank Test). Similarly, patients
with methylated WIF1 gene had significantly shorter me-
dian PFS time (1.1 months, 95% CI, 95% CI, 1.0-1.2) as
compared to those with unmethylated WIF1 gene
(5.4 months, 95% CI, 3.5-7.4) (P = 0.006, Logrank Test)
(Figure 2B). We did not find association between epigen-
otype of other Wnt antagonists and PFS in response to
the TKI therapy (Additional file 1: Figure S2 A-F). More-
over, after adjusted by age, gender, histology of the can-
cer, smoking status, and line of treatment, the
methylation of SFRP5 gene was still significantly asso-
ciated with a shorter PFS (P = 0.008; harzard ratio, 2.165,
95% CI, 1.2-3.8; Cox proportional hazards models of sur-
vival analysis), while the methylation of WIF1 gene was
no longer associated with a shorter PFS (P = 0.224; haz-
ard ratio, 1.804, 95% CI, 0.7-4.7; Cox proportional
hazards models of survival analysis) (Table 4). Taken to-
gether, our results suggested that the methylation status
of SFRP5 might be able to predict the PFS in response
to the TKI therapy.
Similar to the previous discovery [27], we also found
that the median PFS time for patients with EGFR muta-
tions (8.3 months, 95% CI, 5.5-11.1) was significantly
longer than the median PFS for patients with wide-type
EGFR (2.0 months, 95% CI, 1.5-2.5) (P = 0.009, LogrankTable 4 Cox proportional hazard regression analysis of
gender, age, histology, smoking status, EGFR mutation,
WIF1 methylation and SFRP5 methylation for
progression-free survival (PFS)
Variable P value Hazard ratio
(95% CI)








Lines of Treatment 0.302 0.807
(first line/non-first line) (0.537-1.213)
EGFR Mutation 0.024 0.656
(mutation/wide type) (0.455-0.945)
SFRP5 Methylation 0.008 2.165
(methylated/unmethylated) (1.226-3.823)
WIF1 Methylation 0.224 1.804
(methylated/unmethylated) (0.697-4.674)test) (Figure 2C). This is still valid when tested by Cox
proportional hazards model of survival analysis
(P = 0.024; hazard ratio, 0.656, 95% CI, 0.5-0.9; adjusted
by age, gender, smoking status, histology of the cancer,
and line of treatment). More interestingly, we found that
in the subgroup of patients with adenocarcinoma and
EGFR mutation, the ones with methylated SFRP5 had a
significantly shorter PFS (2.0 months), as compared to
the ones with unmethylated SFRP5 (9.0 months)
(P = 0.013, Logrank Test) (Figure 2D).
Epigenotype of Wnt antagonists and overall survival rate
(OS)
To test whether the epigenotype of Wnt antagonists can
predict the clinical outcome of the TKI therapy, we first
investigated the association of DNA methylation of the
Wnt antagonists and overall survival rate in our patient
cohort. Nine patients (6.5%) were lost during the follow-up
period of our study. The median OS time was 27.4 months
(ranging from 3.0 to 93.1 months). Interestingly, patients
with methylated WIF1 genes had significantly reduced
overall survival time (P=0.006, Logrank Test) (Figure 3B),
while the epigenotypes of SFRP5 (Figure 3A), SFRP1,
SFRP2, DKK3, APC, and CDH1 (Additional file 1: Figure
S3 A-E), as well as the genotype of EGFR (Figure 3C) were
not associated with OS in our patients.
Correlation between Wnt antagonist methylation and
Progression-free survival in platinum-based
chemotherapy
In order to decide if WIF-1 and sFRP5 are TKIs specific
biomarkers related to PFS of TKIs treatment, we mean-
while analyzed the association of chemotherapy with the
epigenotype of Wnt antagonists in 63 patients out of the
whole group, who once took platinum-based chemother-
apy as first-line treatment. We failed to find significant
differences in PFS between patients with or without
sFRP5 methylation (3.2 ms, 95% CI 2.01-4.5 vs 4.3 ms,
95% CI 2.5-6.2, respectively, P = 0.487). We did not find
differences in PFS between patients with or without
WIF-1 methylation (3.2 ms, 95% CI 1.89-4.67 vs 2.0 ms,
95% CI 1.71-2.36 P = 0.798) either. We accidentally
found discrepancy in PFS between patients with or with-
out sFRP1 methylation (1.8 ms,95% CI, 1.50-2.09 vs
3.0 ms 95% CI, 1.9-4.0, P = 0.017). However, this statisti-
cally significant difference in PFS remains limited for
patients in clinical practice.
Discussion
Recent studies have demonstrated that cancer is as
much an epigenetic disease as it is a genetic disease
(Iacobuzio-Donahue). Therefore, in addition to genetic
alterations, changes in epigenetic features such as CpG
DNA methylation status of specific gene loci also mark
Figure 3 Kaplan-Meier curves are shown comparing the overall survival of patients with different epigenotypes of SFRP5 (A), WIF1 (B),
or different genotype of EGFR (C).
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methylation of Wnt antagonist SFRP5 gene before treat-
ment, independent of the genotype of EGFR gene, corre-
lated with decreased progression free survival rate in
NSCLC patients in response to the EGFR-TKI therapy.
To our knowledge, this is the first report indicating that
DNA methylation at specific gene loci in patient may
predict drug response to the EGFT-TKI therapy.
Both genetic and epigenetic risk factors for NSCLC
have been studied extensively. Suzuki et al [23] has
reported that methylation of the Wnt antagonist DKK3
correlated with low survival rate in NSCLC patients,
despite of the different therapies patients received.
However, in our study, we did not find significant dif-
ference in the EGFR-TKI responses between patient
groups with or without methylated DKK3 (Additional
file 1: Figure S2 and S3). In contrast, our results sug-
gested epigenotype of SFRP5 provide better prognostic
estimation for the EGFR-TKI response, comparing to
other Wnt antagonists.
SFRP5 is a member of the SFRP protein family con-
taining a cysteine-rich domain homologous to the puta-
tive Wnt-binding site of Frizzled proteins. It acts as
soluble antagonist of Wnt signaling and is highly
expressed in the retinal pigment epithelium, and moder-
ately expressed in the pancreas ("Entrez Gene: SFRP5
secreted frizzled-related protein 5"). Previous studies
has identified association of SFRP5 promoter hyper-
methylation with Acute myeloid leukemia [29], ovarian
cancer [30], gastric cancer [31], oral squamous cell
carcinoma [32], pancreatic cancer [33] and breast
cancer [34].
We found that hypermethylation of SFRP5 predicted
worse outcomes of the EGFR-TKI therapy. Therefore,SFRP5 DNA methylation status may serve as a prognostic
molecular marker for appropriately predicting whether
NSCLC patients would benefit from the EGFR-TKI ther-
apy. Especially, it is interesting that in the subgroup with
adenocarcinoma and EGFR mutation, patients with sFRP5
methylation have a significantly shorter PFS than those
without sFRP5 methylation, While in nonsmokers without
EGFR mutation, patients without sFRP1 methylation
have a longer PFS compared with patients with its
methylation(9.7 ms vs 2.0 ms, p = 0.05). Based on
these results, we can make a hypothesis that activa-
tion of Wnt signaling by antagonist methylation could
confer tumors the characters of stem cell, which con-
sequently causes tumors resistant to EGFR TKIs ther-
apy by generating acquired resistance, such as MET
amplification or changes of PTEN tumor suppressor
activity and so on. Further study is needed to validate
this hypothesis.Conclusions
In conclusion, our study revealed that sFRP5 may be an
independent factor affecting PFS during long time main-
tenance of TKIs therapy. Furthermore, the simple, PCR-
based detection method of DNA methylation may be
more feasible as clinical tests, compared to protein or
RNA expression detection in clinics. Both general DNA
methylation inhibitors and Wnt-pathway-targeting antic-
ancer drugs are under development [35,36]. Our results
that linked Wnt antagonist hypermethylation and EGFR-
TKI response suggest that the treatment paradigm com-
bining epigenetic drugs and EGFR-TKI may be a poten-
tial and attractive therapeutic option for patients with
NSCLC.
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Additional file 1: Figure S1. Methylated and unmethyalted bands of
Wnt antagonist genes and wild/mutant EGFR. S1: The example graphs of
methylated and unmethyalted bands of Wnt antagonist genes (A) and
EGFR wild (B) and mutation types (C, D) by methylation specific PCR and
DHPLC respectively. Figure S2 PFS with different epigenotypes of Wnt
antagonist genes. Figure2S A-F.Kaplan-Meier curves of comparing the
progression free survival of patients with different epigenotypes of SFRP1
(A), SFRP2 (B), DKK3 (C), APC (D), CDH1 (E) and combination analysis (F).
Figure S3 OS with different epigenotypes of Wnt antagonist genes.
Figure3S A-F. Kaplan-Meier curves of comparing the overall survival of
patients with different epigenotypes of SFRP1 (A), SFRP2 (B), DKK3 (C),
APC (D), CDH1 (E) and combination analysis (F).
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